<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04229901</url>
  </required_header>
  <id_info>
    <org_study_id>HEP102</org_study_id>
    <nct_id>NCT04229901</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Efficacy and Safety of HepaStem in Patients With Acute on Chronic Liver Failure (ACLF)</brief_title>
  <acronym>DHELIVER</acronym>
  <official_title>Randomized, Placebo-controlled, Double Blind, Multi-centre Phase IIb Study to Evaluate the Efficacy and Safety of HepaStem in Patients With Acute on Chronic Liver Failure (ACLF</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Promethera Biosciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Promethera Biosciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an interventional, double blind, randomized (2:1), and placebo-controlled study of 1
      dose regimen of HepaStem in patients recently diagnosed (≤1 week) with ACLF grade 1 or 2 on
      top of Standard of Care (SoC), and for whom the diagnosis is not resolved on the day of
      infusion.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2020</start_date>
  <completion_date type="Anticipated">November 2023</completion_date>
  <primary_completion_date type="Anticipated">February 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival proportion 90 days post-first infusion.</measure>
    <time_frame>90 days post first infusion</time_frame>
    <description>Overall Survival proportion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Transplant-free survival proportion 90 days post-first infusion.</measure>
    <time_frame>90 days post first infusion</time_frame>
    <description>Liver Transplant-free survival proportion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver function parameters up to 1-year post-infusion</measure>
    <time_frame>up to 1-year post first infusion.</time_frame>
    <description>CLIF-C ACLF score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver function parameters up to 1-year post-infusion</measure>
    <time_frame>up to 1-year post first infusion.</time_frame>
    <description>MELD score</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">363</enrollment>
  <condition>Acute on Chronic Liver Failure</condition>
  <arm_group>
    <arm_group_label>HepaStem</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in the HepaStem arm will receive 2 infusions of HepaStem (i.v) at 1.0 millions of cells/kg (7 day interval)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients in the placebo arm will receive 2 infusions of placebo (i.v) (7 day interval)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HepaStem</intervention_name>
    <description>HepaStem will be administered as an intravenous (IV) infusion</description>
    <arm_group_label>HepaStem</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo will be administered as an intravenous (IV) infusion</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:

          -  Initial diagnostic of ACLF, at the investigational site, maximum 3 days before
             signature of the ICF.

          -  Patient with Acute on Chronic Liver Failure Grade 1 or 2 according to the CLIF
             definition*.

          -  Bilirubin value ≥5 mg/dL.

        Main Exclusion Criteria:

          -  ACLF grade 3.

          -  Active uncontrolled bleeding or patient with high risk of short term bleeding up to
             investigator's judgment.

          -  Model for End-Stage Liver Disease (MELD) score &gt;35.

          -  Cerebrovascular, myocardial, limb arterial thrombotic event, or history for both
             thrombotic and hemorrhagic cerebrovascular events within 12 months prior to the
             screening and not considered stabilized by the investigator.

          -  Mechanical ventilation due to respiratory failure, except for hepatic encephalopathy.

          -  Inability to maintain mean BP &gt;60 despite use of vasopressors.

          -  Patients receiving immunosuppressive drugs, except glucocorticoids.

          -  Thrombosis of portal vein.

          -  Underlying cirrhosis due to biliary disease or auto immune hepatitis

          -  Coagulation disturbances defined as (Drolz et al. 2016; Nadim et al. 2016):

               1. fibrinogen &lt;80 mg/dL

               2. platelets &lt;50 x 10³/mm3
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Virginie BARTHEL</last_name>
    <phone>+3210394300</phone>
    <email>virginie.barthel@promethera.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>KU Leuven</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
    <contact>
      <last_name>Frederik Nevens, MD</last_name>
      <phone>03216 34 42 99</phone>
      <email>frederik.nevens@uzleuven.be</email>
    </contact>
    <investigator>
      <last_name>Frederik Nevens, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Multiprofile Hospital for Active Treatment &quot;Dr. Georgi Stranski&quot;</name>
      <address>
        <city>Pleven</city>
        <country>Bulgaria</country>
      </address>
    </facility>
    <contact>
      <last_name>Desislava Lyubomirova, MD</last_name>
      <phone>+359 64 886 501</phone>
      <email>dr_lubomirova@abv.bg</email>
    </contact>
    <investigator>
      <last_name>Desislava Lyubomirova, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MMA-Sofia</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
    <contact>
      <last_name>Krum Katsarov, MD</last_name>
      <phone>+35 988 7303 779</phone>
      <email>krum.katzarov@vma.bg</email>
    </contact>
    <investigator>
      <last_name>Krum Katsarov, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Bulgaria</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 6, 2020</study_first_submitted>
  <study_first_submitted_qc>January 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 18, 2020</study_first_posted>
  <last_update_submitted>January 11, 2020</last_update_submitted>
  <last_update_submitted_qc>January 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Failure</mesh_term>
    <mesh_term>Hepatic Insufficiency</mesh_term>
    <mesh_term>End Stage Liver Disease</mesh_term>
    <mesh_term>Acute-On-Chronic Liver Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

